These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 18396243

  • 1. Risk factors for bleeding during anticoagulation of atrial fibrillation in older and younger patients in clinical practice.
    Abdelhafiz AH, Wheeldon NM.
    Am J Geriatr Pharmacother; 2008 Mar; 6(1):1-11. PubMed ID: 18396243
    [Abstract] [Full Text] [Related]

  • 2. Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic.
    Abdelhafiz AH, Wheeldon NM.
    Clin Ther; 2004 Sep; 26(9):1470-8. PubMed ID: 15531009
    [Abstract] [Full Text] [Related]

  • 3. Anemia, hypoalbuminemia, and renal impairment as predictors of bleeding complications in patients receiving anticoagulation therapy for nonvalvular atrial fibrillation: a secondary analysis.
    Abdelhafiz AH, Myint MP, Tayek JA, Wheeldon NM.
    Clin Ther; 2009 Jul; 31(7):1534-9. PubMed ID: 19695402
    [Abstract] [Full Text] [Related]

  • 4. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L.
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [Abstract] [Full Text] [Related]

  • 5. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
    Arch Intern Med; 1996 Feb 26; 156(4):409-16. PubMed ID: 8607726
    [Abstract] [Full Text] [Related]

  • 6. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
    Agarwal S, Bennett D, Smith DJ.
    Am J Cardiovasc Drugs; 2010 Feb 26; 10(1):37-48. PubMed ID: 20104933
    [Abstract] [Full Text] [Related]

  • 7. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice.
    Caro JJ, Flegel KM, Orejuela ME, Kelley HE, Speckman JL, Migliaccio-Walle K.
    CMAJ; 1999 Sep 07; 161(5):493-7. PubMed ID: 10497604
    [Abstract] [Full Text] [Related]

  • 8. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 9. Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study.
    Ripley TL, Harrison D, Germany RE, Adamson PB.
    Clin Ther; 2010 Mar 24; 32(3):506-14. PubMed ID: 20399987
    [Abstract] [Full Text] [Related]

  • 10. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years.
    Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D.
    J Am Coll Cardiol; 2009 Sep 08; 54(11):999-1002. PubMed ID: 19729116
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population.
    Currie CJ, McEwan P, Emmas C, Morgan CL, Peters JR.
    Curr Med Res Opin; 2005 Dec 08; 21(12):1905-13. PubMed ID: 16368039
    [Abstract] [Full Text] [Related]

  • 13. Risks of oral anticoagulant therapy with increasing age.
    Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR.
    Arch Intern Med; 2005 Jul 11; 165(13):1527-32. PubMed ID: 16009869
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department.
    Anthony CJ, Karim S, Ackroyd-Stolarz S, Fry A, Murphy NG, Christie R, Zed PJ.
    Ann Pharmacother; 2011 Jul 11; 45(7-8):881-7. PubMed ID: 21750309
    [Abstract] [Full Text] [Related]

  • 16. Thromboembolic and/or bleeding complications in patients under oral anticoagulation followed at a tertiary hospital.
    Pelicano N, Branco LM, Pinto A, Sá A, Timóteo AT, Feliciano J, Fiarresga A, Agapito AF, Palma MC, Quininha J.
    Rev Port Cardiol; 2005 Jul 11; 24(7-8):957-68. PubMed ID: 16240682
    [Abstract] [Full Text] [Related]

  • 17. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
    Lip GY, Frison L, Halperin JL, Lane DA.
    J Am Coll Cardiol; 2011 Jan 11; 57(2):173-80. PubMed ID: 21111555
    [Abstract] [Full Text] [Related]

  • 18. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation.
    Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S.
    Circulation; 2007 May 29; 115(21):2689-96. PubMed ID: 17515465
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M, AFFIRM Investigators.
    Am Heart J; 2005 Apr 29; 149(4):650-6. PubMed ID: 15990748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.